Key clinical point: Obinutuzumab consolidation after chemoimmunotherapy for B-cell chronic lymphocytic leukemia (B-CLL) helps eradicate minimal residual disease (MRD) and prolong progression-free survival.

Major finding: Out of 14 patients who were MRD positive after chemoimmunotherapy and randomized to obinutuzumab, 10 achieved bone marrow MRD negativity, and 13 achieved peripheral blood MRD negativity by 6 months.

Study details: The seamless phase 2/3 GALACTIC trial of 48 patients.

Disclosures: The GALACTIC trial was developed by the GALACTIC Trial Management Group with the support of the UKCLL/NCRI CLL Clinical Trials Subgroup. The trial is funded by Cancer Research UK and Roche and sponsored by the University of Leeds. Dr. Munir reported having no disclosures.